曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴血脂异常的临床研究

Clinical Study of Trimetazidine Combined with Atorvastatin Calcium in the Treatment of Coronary Heart Disease Angina Pectoris with Dyslipidemia

目的研究曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴血脂异常的临床疗效。方法选择2017年3月～2018年5月在我院治疗的124例冠心病心绞痛伴血脂异常患者,将其随机分为对照组和观察组,各62例。对照组口服阿托伐他汀钙,观察组在此基础加用曲美他嗪,观察两组临床疗效、心绞痛发作情况及不良反应,比较两组患者TC、TG、LDL-C、HDL-C变化水平。结果观察组治疗总有效率高于对照组(88.70%vs 67.74%),差异有统计学意义(P<0.05);治疗后观察组TC、TG、LDL-C水平低于对照组,HDL-C水平高于对照组,差异均有统计学意义(P<0.05);观察组心绞痛发作次数(2.10±1.12)次/周、持续时间(2.27±1.18)min,低于对照组的发作次数(2.82±1.30)次/周、持续时间(2.84±1.32)min,差异有统计学意义(P<0.05);观察组不良反应发生率与对照组对比(3.22%vs 4.83%),差异无统计学意义(P>0.05)。结论曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴血脂异常疗效显著,可减少心绞痛发作次数,缩短发作时间,有效改善患者血脂水平,且临床用药安全。

Objective To study the clinical efficacy of trimetazidine combined with atorvastatin calcium in the treatment of coronary heart disease angina pectoris with dyslipidemia.Methods A total of 124 patients with coronary heart disease angina pectoris and dyslipidemia who were treated in our hospital from March 2017 to May 2018 were randomly divided into control group and observation group, 62 cases each. The control group received oral atorvastatin calcium.The observation group was given trimetazidine on this basis. The clinical efficacy, coronary heart disease angina pectoris and adverse reactions were observed. The changes of TC, TG, LDL-C and HDL-C in the two groups were compared. Results The total effective rate of the observation group was higher than that of the control group （88.70% vs 67.74%）. The difference was statistically significant （P〈0.05）. The levels of TC, TG and LDL-C in the observation group were lower than those in the control group after treatment.The level of HDL-C was higher than that of the control group,the difference was statistically significant（P〈0.05）. The number of angina attacks in the observation group （2.10±1.12） times/week and duration（2.27±1.18） min,the number of episodes was lower than that of the control group（2.82±1.30） times/week, duration（2.84±1.32） min, the difference was statistically significant（P〈0.05）. The incidence of adverse reactions in the observation group was compared with the control group（3.22% vs 4.83%）, the difference was not statistically significant（P〉0.05）. Conclusion Trimetazidine combined with atorvastatin calcium is effective in the treatment of coronary heart disease angina pectoris with dyslipidemia. It can reduce the number of angina attacks, shorten the onset time, effectively improve the blood lipid level of patients, and the safety of clinical medication.